Lyndra Therapeutics adds Helene Madonick and Ashish Singh to its Board of Directors and announces Kyle Haraldsen as CTO

– USA, MA –  Lyndra Therapeutics, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced the appointments of Helene Madonick, J.D., and Ashish Singh to its Board of Directors, bringing relevant expertise in global healthcare law, strategy and operations to the board.

“Helene and Ashish are strong additions to the board bringing experience and perspective that will be invaluable in guiding the company to realize its full potential,” said co-founder and executive chair, Amy Schulman.

The company also announced the appointment of Kyle Haraldsen as CTO.

“Kyle brings a depth of experience in all facets of technical operations, strategy, product innovation, supply chain, and manufacturing,” said CEO Dr. Patricia Hurter.

About Kyle B. Haraldsen

Kyle Haraldsen has more than 20 years of experience, most recently as CTO of Saniona, and spans technical operations, product development, supply chain management, manufacturing, and project management. At Saniona, Haraldsen led efforts to develop a complex long-acting multi-product formulation of their lead asset. He has helped launch numerous nanoparticulate, hormone, peptide, and drug-device combination products. At Lyndra, he will be responsible for product and platform R&D activities for the LYNX™ drug delivery platform and manufacturing, including the build-out of the company’s automated continuous manufacturing facility.

About Helene Madonick

Helene Madonick began her legal career in Washington, D.C. at Arnold & Porter, where she represented pharmaceutical, medical device, and biotech companies in the US and internationally. In her time at the Bill & Melinda Gates Foundation, she oversaw legal operations for their international offices, led legal services for the Global Health Division, and served as Interim Director for the Gender Equality Program Strategy Team. She currently serves on the Board of Directors of the Bill & Melinda Gates Medical Research Institute.

About Ashish Singh

Ashish Singh is Senior Partner and former Healthcare Global Practice Leader for Bain & Company. In addition to leading the organization’s healthcare services and building its payer-provider practice, Singh has worked in virtually every industry on aspects of strategy, operations, and organization. His healthcare advisory work includes three of the five largest US healthcare services companies and healthcare-related M&A and portfolio work for several major private equity clients. He served for six years on the firm’s Global Board of Directors.

About Lyndra Therapeutics

Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, which would benefit from dramatically reduced dosing frequency. Lyndra’s lead product candidate, oral weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies that include oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill, and oral biweekly ivermectin for malaria eradication. Since the founding of Lyndra, the company has received funding from the Bill & Melinda Gates Foundation, the NIH, AbbVie, and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA, and has a state-of-the-art GMP manufacturing facility in Lexington, MA.

For more information, visit https://lyndra.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.